ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.
7/8/2022
Enterin brings a unique steroid close to market with help from Pfizer. Pfizer is the world’s largest drug company, and its visibility has only grown in the past 2 years after its launch of both a vaccine and a therapy for COVID-19. Together, those products will generate about $54 billion in sales for Pfizer this year.
7/4/2022
LiquiGlide®, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, Aon plc (NYSE: AON), a leading global professional services firm, and Atlas Credit Partners, an asset management firm focused on value-oriented credit investments, today announced the completion of an intellectual-property based financing deal that provides LiquiGlide with $35 million to expand its commercial activities and continue to develop its platform for new applications.
4/22/2022
Today VERIGRAFT announces that the company has successfully reached the safety assessment milestone in the first patient of the TECVI-1 clinical trial in which the safety of P-TEV for the treatment of CVI is investigated.
3/2/2022
Intelinair and Airbus announced today a multi-year collaboration agreement that will provide high-resolution, Airbus satellite imagery as an input to Intelinair’s artificial intelligence (AI) powered crop analytics AGMRI® platform to deliver a complete view of every acre, every field from planting to harvest.
2/23/2022
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the conclusion of a randomized, placebo-controlled, double-blind Phase 2b (KARMET) study involving 150 patients with Parkinson’s Disease (PD).
1/27/2022
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of ZYNLONTA® (loncastuximab tesirine-lpyl) for all hematologic and solid tumor indications in Japan.
1/18/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
12/20/2021
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Marketing Authorization Application (MAA) for ZYNLONTA®, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the European Medicines Agency (EMA). Validation of the application enables the evaluation process by the EMA’s Committee for Medicinal Products for Human Use (CHMP) to begin.
10/29/2021
Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company.
10/7/2021
Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed with ZYNLONTA®in a pivotal Phase 2 clinical trial in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in China.
9/29/2021
Pablo Graiver, founder and former CEO of Antidote, has joined Drumroll Health as its new Chief Executive Officer. The company also announced that industry veterans Paul Bleicher and Ritesh Patel have joined the Advisory Board, alongside Craig Lipset and Jennifer Levin Carter.
9/29/2021
In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations
9/27/2021
Intelinair has raised $20 million in Series B funding to continue to scale the company and its flagship crop intelligence platform, AGMRI®.
9/24/2021
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA®, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma (DLBCL).
9/13/2021
ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).
8/26/2021
LiquiGlide, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced the launch of zero-waste packaging for the health and beauty industry.
8/24/2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
8/20/2021
Transparency Life Sciences, a digital health startup that develops technology solutions to foster closer partnerships between patients and health professionals, today unveiled a new corporate identity and company name: Drumroll Health.
8/10/2021
The U.K.-based startup is clearly making waves amongst investors. It has now raised yet another seed funding round, this time totalling $2.5 million, from 65 health-tech and consumer-tech investors, taking its total raised to $5 million.
8/4/2021
